Search

Your search keyword '"Lejeune, Stéphane"' showing total 26 results
Start Over Author "Lejeune, Stéphane"
26 results on '"Lejeune, Stéphane"'

1. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Author

Blay, Jean-Yves, Casali, Paolo, Ray-Coquard, Isabelle, Seckl, Michael J., Gietema, Jourik, de Herder, Wouter W., Caplin, Martyn, Klümpen, Heinz-Josef, Glehen, Olivier, Wyrwicz, Lucjan, Peeters, Robin, Licitra, Lisa, Girard, Nicolas, Piperno-Neumann, Sophie, Kapiteijn, Ellen, Idbaih, Ahmed, Franceschi, Enrico, Trama, Annalisa, Frezza, Anna-Maria, Hohenberger, Peter, Hindi, Nadia, Martin-Broto, Javier, Schell, Johanna, Rogasik, Muriel, Lejeune, Stephane, Oliver, Kathy, de Lorenzo, Francesco, and Weinman, Ariane

Published
2024
Full Text
View/download PDF

2. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

Author

Smith, Emma Jane, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Campi, Riccardo, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Gandaglia, Giorgio, Crosti, Daniele, Meoni, Massimiliano, Garzonio, Roberto, Bangma, Chris, Roobol, Monique, Remmers, Sebastiaan, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Beyer, Katharina, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Auffray, Charles, Balaur, Irina-Afrodita, Taibi, Nesrine, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Omar, Imran, MacLennan, Sara, MacLennan, Steven, Tripathee, Sheela, Huber, Johannes, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Asiimwe, Alex, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Kedhagae, Siddhanth, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Dau, Chad, Papineni, Kishore, Wang-silvanto, Jing, Hass, Steve, Snijder, Robert, Doyé, Verena, Wang, Xuewei, Garnham, Andy, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Casariego, Joaquin, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Derkits, Sahra, Licour, Muriel, Ang, Michelle, Payne, Sarah, Yong, Alan, Thompson, Lucy, Le Mare, Sophia, Bussmann, Michael, Köhler, Inken, Juckeland, Guido, Kotik, Daniel, MacLennan, Sara J., Mastris, Ken, Hooker, Gary, Greene, Robert, Briers, Erik, Omar, Muhammad Imran, Healey, Jemma, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Roobol, Monique J., and N’Dow, James

Published
2021
Full Text
View/download PDF

4. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Smith, Emma, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Abbott, Tom, Mastris, Ken, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Fossati, Nicola, Pang, Karl, Campi, Riccardo, Greco, Isabella, Gacci, Mauro, Serni, Sergio, Bjartell, Anders, Lonnerbro, Ragnar, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Gandaglia, Giorgio, Faticoni, Martina, Grant office, Bangma, Chris, Jongerden, Maria, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Lejeune, Stephane, Colette, Laurence, Caputova, Simona, Poli, Delielena, Byrne, Sophie, Fialho, Luz, Rowland, Ashley, Tapela, Neo, Di Flora, Nicola, Apostolidis, Kathi, Lemair, Valerie, De Meulder, Bertrand, Auffray, Charles, Taibi, Nesrine, Hijazy, Ayman, Saporta, Albert, Sun, Kai, Power, Shaun, Zounemat Kermani, Nazanin, van Bochove, Kees, Tafreshiha, Azadeh, Bernini, Chiara, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Tripathee, Sheela, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Gasi Tandefelt, Delila, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Tames Grijalva, Monica, Evans-Axelsson, Susan, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Waldeck, Reg, Bruno, Amanda, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Steinbeisser, Carl, Maass, Monika, Torremante, Patrizia, Dochy, Emmanuelle, Pisa, Federica, Voss, Marc Dietrich, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Wang, Xuewei, Lambrecht, Mark, Wolfinger, Russ, Eid, Sherinne, Palanisamy, Soundarya, Haque, Samiul, Antoni, Laurent, Servan, Angela, Pascoe, Katie, Robinson, Paul, Lencart, Joana, Jaton, Bertrand, Turunen, Heidi, Kilkku, Olavi, Pohjanjousi, Pasi, Voima, Olli, Nevalaita, Liina, Punakivi, Keijo, Seager, Sarah, Ratwani, Shilpa, Grzeslak, Katarzyna, Brash, James, Longden-Chapman, Elaine, Burke, Danny, Licour, Muriel, Payne, Sarah, Yong, Alan, Lujan, Flavia, Le Mare, Sophia, Hendrich, Jan, Bussmann, Michael, Juckeland, Kotik, Reich, Christian, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

8. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres

Author

Doran Peter, Cooney Margaret, Gaynor Siobhan, Voko Zoltán, Wittenberg Michael, Schade-Brittinger Carmen, Leizorovicz Alan, Gueyffier Francois, Lauritsen Jens, Salas Nader, Yang Qin, Ohmann Christian, Kuchinke Wolfgang, Maggioni Aldo, Lorimer Andrea, Torres Ferràn, McPherson Gladys, Charwill Jim, Hellström Mats, and Lejeune Stéphane

Subjects
Medicine (General), R5-920
Abstract

Abstract Background The use of Clinical Data Management Systems (CDMS) has become essential in clinical trials to handle the increasing amount of data that must be collected and analyzed. With a CDMS trial data are captured at investigator sites with "electronic Case Report Forms". Although more and more of these electronic data management systems are used in academic research centres an overview of CDMS products and of available data management and quality management resources for academic clinical trials in Europe is missing. Methods The ECRIN (European Clinical Research Infrastructure Network) data management working group conducted a two-part standardized survey on data management, software tools, and quality management for clinical trials. The questionnaires were answered by nearly 80 centres/units (with an overall response rate of 47% and 43%) from 12 European countries and EORTC. Results Our survey shows that about 90% of centres have a CDMS in routine use. Of these CDMS nearly 50% are commercial systems; Open Source solutions don't play a major role. In general, solutions used for clinical data management are very heterogeneous: 20 different commercial CDMS products (7 Open Source solutions) in addition to 17/18 proprietary systems are in use. The most widely employed CDMS products are MACRO™ and Capture System™, followed by solutions that are used in at least 3 centres: eResearch Network™, CleanWeb™, GCP Base™ and SAS™. Although quality management systems for data management are in place in most centres/units, there exist some deficits in the area of system validation. Conclusions Because the considerable heterogeneity of data management software solutions may be a hindrance to cooperation based on trial data exchange, standards like CDISC (Clinical Data Interchange Standard Consortium) should be implemented more widely. In a heterogeneous environment the use of data standards can simplify data exchange, increase the quality of data and prepare centres for new developments (e.g. the use of EHR for clinical research). Because data management and the use of electronic data capture systems in clinical trials are characterized by the impact of regulations and guidelines, ethical concerns are discussed. In this context quality management becomes an important part of compliant data management. To address these issues ECRIN will establish certified data centres to support electronic data management and associated compliance needs of clinical trial centres in Europe.

Published
2010
Full Text
View/download PDF

9. Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making

Author

Lejeune, Stéphane, Saesen, Robbe, and Quaglio, Gianluca

Abstract

Background: The current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients that will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of a research gap between the pre-approval development of anticancer medicines and their post-registration use in real-life clinical practice. This gap could potentially be bridged by transitioning towards a patient-centered paradigm that places a strong emphasis on treatment optimization, which strives to optimize the way health technologies are applied in a real-world environment. However, questions remain concerning the ideal features of treatment optimization studies and their acceptability among key stakeholders.Objectives: The aim of this study was to explore the views of key stakeholders in the drug development process regarding the concept of treatment optimization.Methods: Semi-structured interviews were conducted between December 2018 and May 2019 with 26 participants across ten EU Member States and six different stakeholder groups, including academic clinicians as well as representatives of patient organizations, regulator and payer authorities, health technology assessment agencies and industry.Results: Based on the input of the experts interviewed, clarification was obtained regarding the optimal features of treatment optimization studies in terms of their conduct, funding, timing, design and setting. Moreover, a number of opportunities and challenges of undertaking such trials were identified. Inter-stakeholder discussion during their design was seen as desirable. There was also broad support among the participants for regulatory measures to facilitate treatment optimization, although there was no agreement on the optimal scale and nature of these initiatives. Furthermore, the interviewees believed that the evidence strength of well-designed treatment optimization studies performed according to rigorous quality standards is greater than or at least equal to that of classical clinical trials. In addition, there was a strong consensus that the results of treatment optimization studies should be taken into account during the decision-making of regulators, payers and/or clinicians. Conclusions: Stakeholders involved in drug development consider treatment optimization studies to be valuable tools to address current evidence gaps and support their implementation into the existing research framework.

Published
2017

10. Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

Author

Saesen, Robbe, Lejeune, Stéphane, Quaglio, Gianluca, Lacombe, Denis, and Huys, Isabelle

Subjects
DRUG development, DRUG registration, TECHNOLOGY assessment, SEMI-structured interviews, MEDICAL technology, STAKEHOLDERS
Abstract

Background: The current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients who will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of a research gap between the pre-approval development of anticancer medicines and their post-registration use in real-life clinical practice. This gap could potentially be bridged by transitioning toward a patient-centered paradigm that places a strong emphasis on treatment optimization, which strives to optimize the way health technologies are applied in a real-world environment. However, questions remain concerning the ideal features of treatment optimization studies and their acceptability among key stakeholders. Objectives: The aim of this study was to explore the views of key stakeholders in the drug development process regarding the concept of treatment optimization. Methods: Semi-structured interviews were conducted between December 2018 and May 2019 with 26 participants across ten EU Member States and six different stakeholder groups, including academic clinicians as well as representatives of patient organizations, regulatory authorities, health technology assessment agencies, payers, and industry. Results: Based on the input of the experts interviewed, clarification was obtained regarding the optimal features of treatment optimization studies in terms of their conduct, funding, timing, design, and setting. Moreover, a number of opportunities and challenges of undertaking such trials were identified. Inter-stakeholder discussion during their design was seen as desirable. There was also broad support among the participants for regulatory measures to facilitate treatment optimization, although there was no agreement on the optimal scale and nature of these initiatives. Furthermore, the interviewees believed that the evidence strength of well-designed treatment optimization studies performed according to rigorous quality standards is greater than or at least equal to that of classical clinical trials. In addition, there was a strong consensus that the results of treatment optimization studies should be taken into account during the decision-making of regulators, payers, and/or clinicians. Conclusions: Stakeholders involved in drug development consider treatment optimization studies to be valuable tools to address current evidence gaps and support their implementation into the existing research framework. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres

Author

Kuchinke, Wolfgang, primary, Ohmann, Christian, additional, Yang, Qin, additional, Salas, Nader, additional, Lauritsen, Jens, additional, Gueyffier, Francois, additional, Leizorovicz, Alan, additional, Schade-Brittinger, Carmen, additional, Wittenberg, Michael, additional, Voko, Zoltán, additional, Gaynor, Siobhan, additional, Cooney, Margaret, additional, Doran, Peter, additional, Maggioni, Aldo, additional, Lorimer, Andrea, additional, Torres, Ferràn, additional, McPherson, Gladys, additional, Charwill, Jim, additional, Hellström, Mats, additional, and Lejeune, Stéphane, additional

Published
2010
Full Text
View/download PDF

22. Natural linewidth of the Mössbauer level of 119Snm

Author

Lejeune, Stéphane, Dehaes, Jean-Claude, Drymael, Henri Jules, Lejeune, Stéphane, Dehaes, Jean-Claude, and Drymael, Henri Jules

Abstract

The natural linewidth of the 24 keV level of 119Snm has been remeasured by Mössbauer spectroscopy and delayed coincidence giving a half life of 23 ns greater than the standard value of 18.4 ns. © 1970., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1970

23. Étude de la pentacovalence dans les complexes halogénures de trialkylétains avec bases monoaza-aromatiques par spectroscopie Mössbauer

Author

Nasielski, Jacques, Sprecher, N., Devooght, Jacques, Lejeune, Stéphane, Nasielski, Jacques, Sprecher, N., Devooght, Jacques, and Lejeune, Stéphane

Abstract

The Mössbauer spectra of a series of complexes R3SnX + aza-aromatic base have been recorded. It is found that the spectroscopic parameters (IS, QS, or their ratio p) bear no relation whatsoever to structural or electronic properties of the aromatic ligand bound to the tin atom. It is concluded that care should be exercised before drawing quantitative conclusions from Mössbauer data on such complexes. © 1967., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1967

24. Influence de l'autoabsorption sur les mesures absolues de la fraction Mössbauer

Author

Lejeune, Stéphane and Lejeune, Stéphane

Abstract

The influence of self-absorption for Mössbauer f{hook} measurements is considered theoretically and experimentally. Neglecting the ordinary mass attenuation is shown to lead to errors which can be very important for small fractions. Measurements with a stainless steel source are in good agreement with theoretical expressions which take account of ordinary mass attenuation. © 1966., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1966

26. The role of complementary and alternative medicine in the management of early breast cancer: Recommendations of the European Society of Mastology (EUSOMA)

Author

Baum, Michael, Cassileth, Barrie R., Daniel, Rosy, Ernst, Edzard, Filshie, Jacqueline, Nagel, Gerd Arno, Horneber, Markus, Kohn, Michelle, Lejeune, Stéphane, Maher, Jane, Terje, Risberg, and Smith, Wendy B.

Subjects
*BREAST cancer, *ALTERNATIVE medicine, *CANCER patients, *GASTROINTESTINAL diseases
Abstract

Abstract: Patients diagnosed with breast cancer have many needs that for a start include the expectation of cure. Where cure is unlikely there is always a place for hope and spiritual support. Furthermore whether dealing with the early stages or with the advanced disease patients require symptomatic control that encompasses pain relief, control of nausea and vomiting and psychological distress.To achieve all of these goals there is a need that goes beyond the role of scientific medicine. This position papers describes the guidelines for the use of complimentary and alternative medicine (CAM) developed by a workshop on behalf of the European Society of Mastology (EUSOMA). [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results